Alnylam Pharmaceuticals, Inc.
NASDAQAlnylam Pharmaceuticals reports again on August 6 — just one week after the 28% collapse that made its July 30 print one of the most punishing single-day moves in the stock's history. The options market is telling a notably bullish story into this follow-on event, which is striking given the backdrop. The put/call ratio has dropped to 0.47, more than two and a half standard…
Snapshot as of 19 Aug 2026
Alnylam Pharmaceuticals reports again on August 6 — just one week after the 28% collapse that made its July 30 print one of the most punishing single-day moves in the stock's history. The options market is telling a…
Alnylam Pharmaceuticals just delivered the worst single-day drop in recent memory, collapsing 28% on July 30 to $205.48 after its earnings print triggered an immediate and sweeping analyst response. The catalyst was…
Alnylam Pharmaceuticals heads into its July 30 earnings print with the Street broadly bullish but steadily marking down its price targets — a week after the stock shed 3.5% to $271.37. The analyst picture is the…
Alnylam Pharmaceuticals enters the week with its most bullish options configuration of the past year, even as the short-side rebuild that defined early June quietly goes into reverse. The standout this week is in the…
Alnylam Pharmaceuticals enters June with a fresh tension: short sellers are quietly rebuilding positions in a stock the analyst consensus still rates a Buy — but where the share price sits $160 below the average Street…
Alnylam Pharmaceuticals heads into its Q1 2026 earnings today with options traders sending a strikingly bullish signal — the most bullish in at least a year. The put/call ratio dropped to 0.39 on May 19, three standard…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ALNY — free to start on ORTEX.
Sign up for free →Open ALNY on ORTEX